Trial ID or NCT#

NCT02032823

Status

not recruiting iconNOT RECRUITING

Purpose

Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

Official Title

A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Eligibility Criteria

Ages Eligible for Study: 18 Years to 130 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Allison W. Kurian, M.D., M.Sc.
Allison W. Kurian, M.D., M.Sc.
Medical oncologist, Breast specialist, Cancer geneticist
Professor of Medicine (Oncology) and of Epidemiology and Population Health
Melinda L. Telli, M.D.
Melinda L. Telli, M.D.
Medical oncologist, Breast specialist
Associate Professor of Medicine (Oncology)
Douglas W. Blayney
Douglas W. Blayney
Medical oncologist, Breast specialist
Professor of Medicine (Oncology)
George W. Sledge Jr., M.D.
George W. Sledge Jr., M.D.
Medical oncologist, Breast specialist
Professor of Medicine (Oncology)

Contact us to find out if this trial is right for you.

CONTACT

CCTO
(650) 498-7061